Researching AI ophthalmic imaging workflows means separating model capability from integration burden. The primary evidence shows strong internal performance for task-specific models, but limited measurement of combined human–AI workflow outcomes. The immediate review should focus on four questions: which output and modality the model covers, which claims are supported by external validation, which support systems the deployment requires, and which reporting standards exist for labels and model updates. The most useful starting point is therefore not a vendor road map but the gap between published accuracy and documented workflow change.

Model outputs vary more than headline accuracy suggests

Ophthalmic AI research now spans single-task classifiers, structured report generators and multimodal agents. A 2026 Ophthalmology Science study fine-tuned a Llama 3.2 Vision-Instruct model on 43,849 Spectralis circumpapillary B-scans from two glaucoma cohorts to perform quality triage and generate structured reports with sector-wise retinal nerve fiber layer thinning descriptions [2]. The model reported strong text alignment scores, but those metrics measure similarity to reference wording, not clinical decision impact. For a deployment team, the relevant fact is that the output is a generated report, which raises different integration and verification questions than a binary screening flag.

A separate agent-based system, AgentEYE, routes fundus photographs and B-scan ultrasonography to specialized tools, retrieves clinical evidence, and generates traceable diagnostic reports [3]. The developers describe retrospective benchmarks and blinded ophthalmologist review as supporting further prospective validation, which is precisely not deployment readiness [3]. The practical distinction for research is whether the system outputs a bounded classification, a generated clinical narrative, or a citation-grounded report. Each implies different monitoring obligations, failure modes and clinician review burdens. A workflow that handles only fundus photographs cannot be assumed to absorb OCT or ultrasound without a second evaluation cycle.

External validation and human–AI workflow evidence remain thin

A 2025 JAMA Network Open diagnostic study assessed AI assistance across 24 clinicians from 12 institutions diagnosing 2,880 age-related macular degeneration risk features in 240 patients over multiple rounds with and without assistance [4]. The authors reported that AI assistance was associated with improved accuracy and time efficiency, then explicitly noted that algorithm explainability and clinician trust remain challenges [4]. That qualification matters for workflow research: even a positive combined human–AI result does not establish the reason for improvement or its durability when the model is embedded in routine scheduling and documentation.

Broader literature reviews reinforce the limitation. One review of 82 studies on AI disease classification across 18 specialties found that only 14 compared performance with health care professionals and only 25 included external validation [4]. The Collaborative Community on Ophthalmic Imaging Working Group has separately noted that benchmarking combined human and AI workflow performance is understudied [4]. Researchers evaluating a new vendor claim should therefore treat an internal test-set area under the curve as necessary but not sufficient. The decisive question is whether the model was tested outside the development cohort in a workflow that resembles the intended deployment setting.

What to request before a local AI ophthalmic imaging pilot

Ask the vendor for the indications for use, which describes the disease or condition and intended patient population evaluated in the premarket submission [8]. Request summaries of training data, internal and external evaluation data, relevant subgroup performance, and any FDA-authorized predetermined change control plan or model update process [1]. Request per-version change notes that flag subgroup-specific performance changes, and confirm whether the model reports output status such as processing, inferenced or rejected for verification [1].

Infrastructure and standards determine whether research findings transfer

An orders-based imaging workflow at one pediatric ophthalmology setting integrated thirteen devices across six modalities and five locations using DICOM modality worklists, HL7 interfaces and enterprise archive storage [6]. Post-implementation, 16,267 imaging studies were completed with 40–86% reductions in clicks and keystrokes depending on modality, although optical coherence tomography and B-scan ultrasound took longer [6]. This is infrastructure data, not AI performance data. It illustrates the more consequential finding that many ophthalmic modalities output a DICOM-compliant PDF report rather than raw images, which can limit longitudinal comparison and display protocol development [6]. Any AI workflow inherits these same constraints.

Standards work is proceeding in parallel. The ACR–SIIM practice parameter adopted in 2026 covers governance, local acceptance testing, real-world performance monitoring and non-FDA-regulated models [1]. It encourages manufacturers to provide training data summaries, subgroup performance, per-version change notes and inference transparency [1]. A consensus-based reference standard for labeling age-related macular degeneration reached agreement on late AMD referral thresholds but not on pigment change detection or screening age thresholds [5]. The practical consequence is that even the ground-truth labels for training and validation remain partially unsettled, which should temper any claim of objective benchmark comparability across AMD screening tools.

A conservative evaluation plan can be built without a vendor pilot

A research question often arrives before any product shortlist. For a hypothetical clinic considering AI-assisted OCT report generation, the evaluation could proceed in three documented phases. Phase one would inventory the imaging modalities, output formats and existing order workflows, in the manner measured by the pediatric ophthalmology implementation study [6]. Phase two would identify whether the candidate model reports external validation populations, subgroup performance and version-specific change notes, consistent with the 2026 practice parameter [1]. Phase three would define a restricted read task, not full clinical adoption.

The restricted task should require a treating clinician to review every AI output before documentation, with disagreement rates logged separately from model accuracy. If the candidate system cannot export per-version output status or inference transparency, the deployment should be paused regardless of internal accuracy [1]. The educational review in Ophthalmology Science supports this posture by recommending that clinicians examine dataset diversity, label quality and severity coverage before believing a published model [7]. That is the correct research stance: treat the literature as a source of testable hypotheses, not as proof that a workflow will improve in your setting.